CYP3A4*1G基因多态性与紫杉醇血药浓度的关系研究

Study on the Relationship of CYP3A4*1G Gene Polymorphism and Plasma Concentrations of Paclitaxel

目的:研究乳腺癌化疗患者CYP3A4*1G基因多态性与紫杉醇血药浓度的关系。方法:采用高效液相色谱(HPLC)法测定紫杉醇血药浓度,以聚合酶链式反应-限制性片段长度多态性法(PCR-RFLP)检测CYP3A4*1G基因多态性,探讨使用紫杉醇化疗患者CYP3A4*1G基因型与紫杉醇血药浓度的关系。结果:不同基因型患者紫杉醇血药浓度分别为:CC型(0.097 6±0.042 9)μg/ml、CT型(0.102 4±0.046 6)μg/ml、TT型(0.106 5±0.036 7)μg/ml。3种基因型之间,紫杉醇血药浓度差异无统计学意义(P>0.05)。结论:CYP3A4*1G基因突变对紫杉醇血药浓度无影响。

OBJECTIVE：To investigate the relationship between the genetic polymorphism of CYP3A4＊1G and the plasma concentrations of Paclitaxel in the chemotherapy patients with breast cancer. METHODS：The plasma concentrations of paclitaxel were detected with high performance liquid chromatography（HPLC）,and the genetic polymorphism of CYP3A4＊1G was determined using polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） to analysis the relationship between the genotypes of CYP3A4＊1G and the plasma concentrations of paclitaxel in the chemotherapy patients with breast cancer. RESULTS：The plasma concentrations of paclitaxel in patients with different genotypes were CC allele（0.097 6±0.042 9）μg/ml,CT allele（0.102 4±0.046 6）μg/ml and TT allele（0.106 5±0.036 7）μg/ml. There were no significant differences of the plasma concentrations of paclitaxel among these 3 genotypes（P〉0.05）. CONCLUSION：There are no relation between the gene mutation of CYP3A4＊1G and the plasma concentrations of Paclitaxel.